<?php include ("code-head.php"); ?>

<body>
<?php include("header.php"); ?>
	
	<main id="content-area">
		<div class="bg-cont">
	
		<article class="single-page">
			
			
			<header class="page-header">
				<div class="container">		
					<h1>Staff M&eacute;dico</h1>					
				</div>
			</header><!-- /.page-header -->
			
			
			<div class="container page-content">

				<section class="detalle-servicio">
					<div class="foto">
						<img src="img/dr_riofrio.jpg" Title="Dr. Mauricio Augusto Riofrío Riofrío">
					</div>
					<div class="text">
						
						<h3>Dr. Mauricio Augusto Riofr&iacute;o Riofr&iacute;o</h3>
						
						<h5>Onc&oacute;logo</h5>
						<ul class="asist">
							<li><strong>Tel&eacute;fonos:</strong> 593 (4) 2449610 - Fax: 593 (4) 2446718</li>
							<li><strong>E-mail:</strong> m_riofrio@hotmail.com</li>
						</ul>
                                          

						<h3>EXPERIENCIA  LABORAL:</h3>
						<ul class="asist">
							<li>1985-1991: Medical Studies at Catholic University of Guayaquil.</li>
							<li>1991-1992: Pregrade Practice at Social Security Hospital and Alejandro’s MANN Child Hospital, Guayaquil - Ecuador</li>
							<li>1992: Internal Medicine and Surgery Doctoral Degree of the Ecuadorian Republic.</li>
							<li>1992-1993: Medical Community Practice for the Ecuadorian Public Health Minister.</li>
							<li>1993-1996: Resident at Internal Medicine Department of M.H.Alcívar Hospital.</li>
							<li>1994-1996: Practice Professor of Clinical Oncology at Catholic University of Guayaquil.</li>
							<li>1994-1996: Fellow of Internal Medicine Department at National Ecuadorian Cancer Institute, SOLCA Guayaquil</li>
							<li>1996-1997: Foreign Resident of Paris Medical College.</li>
							<li>1997-1998: Resident of the Hematology, Immunology and Tumoral Disease Department at Paul Brousse Hospital (Villejuif).</li>
							<li>1998: « Certificat C2 Regulations Cellulairs, Pathologie des Regulations» Biology and Medical Sciences Matrix.</li>
							<li>1998: Certification of Specialist Formation in Clinical Oncology delivered by the Paris XI University.</li>
							<li>Feb 1999-October 2000: Senior Resident of Medicin Department at Gustave Roussy Institut.</li>
							<li>November 2000-October 2001: Chef de Clinique at Oncologist and Hematologist Service of Paul Brousse Hospital, Paris XI University</li>
							<li>1999-2001: ESMO (European Society of Medical Oncology) Fellowship winner.</li>
							<li>August 2002-October 2012 Head of Clinical Oncology Service at Hospital Naval Guayaquil</li>
							<li>Since November 2012 Head of Clinical Oncology Service at M.H. Alcivar Hospital</li>
						</ul>



						<h3>PUBLICATIONS AND POSTERS:</h3>
						<ul class="asist">
							<li>Cervix Carcinoma, In Situ and IA Stade, prognostic and treatment. Oral presentation VII Ecuadorian National Congress of Cancerology, Guayaquil July 1992.</li>
							<li>Invaginación intestinal diagnosticada y reducida por enema baritado. Actas Médicas; Vol. 4 No. 1, 1994 pag.57-61.</li>
							<li>Infarto agudo de miocardio, estudio de 4 años en la unidad de terapia intensiva del Hospital M.H. Alcivar. Actas Médicas; Vol. 4 No. 1, 1994 pag. 90-96.</li>
							<li>Paludismo y derrame pleural, estudio de 2 casos. Actas Médicas; Vol. 4 No. 2, 1994 pag. 144-148.</li>
							<li>Valeur predictive du taux initial de bilirubinemie et de son elevation precoce et transitoire au cours des chimiotherapies comportant du CPT-11, dans la survenue de neutropenie et diarrhee severes. Poster discution XVIIeme Forum de Cancerologie, Paris Mai 1997.</li>
							<li>Bilirubin: Baseline value and transient increase of total bilirubin (BIL) may be used as good predictor of CPT-11’s toxicity. Oral presentation ECCO 9 Hamburg September 1997.</li>
							<li>Oxaliplatin (L-OHP)/CPT11 combination every two weeks: Preliminary results of a phase I study in advanced digestive malignancies. Poster presentation at AACR eighty-ninth Annual Meeting New Orleans, LA - March 1998.</li>
							<li>Ecteinascidin-743 (ET-743) 24 hours continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients (pts). Poster presentation at AACR eighty-ninth Annual Meeting New Orleans, LA - March 1998.</li>
							<li>Baseline serum bilirubin, a good predictor of CPT-11 neutropenia. A pharmacokinetic/Pharmacodynamic (pk/pd) correlation. Poster presentation at AACR eighty-ninth Annual Meeting New Orleans, LA - March 1998.</li>
							<li>Bilirubin (BIL) and SN-38 Metabolism: Pharmacodynamics of CPT-11 Toxicity. Proceedings of ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.</li>
							<li>Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study in solid tumor patients (PTS). Preliminary results. Poster presentation ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.</li>
							<li>CPT11/Oxaliplatin (L-OHP) every two weeks: A phase I study in patients (PTS) with advanced digestive tumors. Poster presentation ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.</li>
							<li>CPT11/Oxaliplatin (L-OHP): Thimidylate sinthase (TS) independent combination with efficacy in 5-FU refractory colorectal cancer (CRC) patients (PTS). Poster presentation ASCO Thirty-fourth Annual Meeting. May 1998 Los Angeles, CA.</li>
							<li>Bilirubin (BIL) and SN-38: Pharmacokinetic/Pharmacodynamics correlation. Poster presentation at 10 th NCI-EORTC symposium on new drugs in cancer therapy. June 1998 Amsterdam.</li>
							<li>Ecteinascidin-743 (ET-743) 24-hour continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients. Poster presentation at 10 th NCI-EORTC symposium on new drugs in cancer therapy. June 1998 Amsterdam.</li>
							<li>CPT-11/oxaliplatin (L-OHP) combination: Comparison of the toxicity of two schedules of administration. Poster presentation at 10 th NCI-EORTC symposium on new drugs in cancer therapy. June 1998 Amsterdam.</li>
							<li>Oxaliplatin (L-OHP)/CPT 11 combination every two weeks. Results of an ongoing phase I study in advanced digestive malignancies. Poster presentation ESMO 23rd congress, November 1998 – Athens, Greece.</li>
							<li>Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study progressive report. Poster presentation ESMO 23rd congress, November 1998 – Athens, Greece.</li>
							<li>Ecteinascidin-743(ET- 743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study, final report. Poster presentation ASCO Thirty-fifth annual meeting. May 1999 Atlanta GA.</li>
							<li>Facteurs Pronostics du Cancer du Sein et Facteurs Prédictifs de la Reponse au Traitement. La Lettre du Cancérologue ; Fevrier 2000, Vol. IX n° 1, pag. 29-35. 3.</li>
							<li>Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.J Clin Oncol. 2001 Mar 1;19(5):1256-65.</li>
							<li>Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.J Clin Oncol. 2001 Mar 1;19(5):1248-55.</li>
							<li>Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes.Ann Oncol. 2001 Sep;12(9):1265-8.</li>
							<li>Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.Cancer. 2001 Nov 1;92(9):2267-72.</li>
							<li>Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.J Clin Oncol. 2004 Mar 1;22(5):890-9.</li>
							<li>A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.Br J Cancer. 2006 Jun 5;94(11):1610-4.</li>
						</ul>


					</div>

				</section>

							
			</div><!-- /.content -->
			
			</article><!-- /#single-page -->
		</div>
	</main><!-- /#content-area -->
	
	<!-- Livemotive -->
	
<?php include("footer.php"); ?>
	
</body>
</html>